SCHEMBL6283673

SCHEMBL6283673

C[C@H](O)Cn1cnc2cc(F)ccc21

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.45
APAF1 O14727 1/20 0.43
PRPS1 P60891 1/20 0.43
GGPS1 O95749 3/20 0.43
FDPS P14324 3/20 0.43
IDO1 P14902 1/20 0.41
MAPT P10636 3/20 0.40
MAPK1 P28482 2/20 0.40
HTT P42858 2/20 0.40
GRIN2B Q13224 1/20 0.40
LMNA P02545 1/20 0.40
GAA P10253 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
PPARG P37231 1/20 0.39
AGER Q15109 4/20 0.39
HSD17B10 Q99714 2/20 0.39
ADORA2A P29274 1/20 0.38
ADORA1 P30542 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29340889 0.88 POLB (0.59) POLBAPAF1PRPS1GGPS1FDPS
SCHEMBL30899625 0.84 PRPS1 (0.43) POLBAPAF1PRPS1GGPS1FDPS
SCHEMBL30697214 0.82 APAF1 (0.51) POLBAPAF1PRPS1GGPS1FDPS
SCHEMBL6285122 0.82 POLB (0.45) POLBAPAF1GGPS1FDPSIDO1
SCHEMBL20985903 0.82 MAPT (0.60) POLBAPAF1GGPS1FDPSIDO1
SCHEMBL6176590 0.82 POLB (0.45) POLBAPAF1GGPS1FDPSIDO1
SCHEMBL6284404 0.81 NPSR1 (0.46) POLBAPAF1GGPS1FDPSMAPT
SCHEMBL6176862 0.81 NPSR1 (0.46) POLBAPAF1GGPS1FDPSMAPT
SCHEMBL19911431 0.79 PRPS1 (0.44) POLBPRPS1MAPTMAPK1HTT
SCHEMBL6760577 0.79 NPC1 (0.51) POLBPRPS1MAPTHTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6875765-B2 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY (US) 2005-04-05 US disclosed
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof WARNER-LAMBERT COMPANY 2003-05-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096826-A1 Arylsulfonamide ethers, and methods of use thereof CASP1, IRAK1, STS POLB 4412/4885APAF1 30/4885PRPS1 2056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.